Samuel Shor, MD, FACP, explores the controversial concept of chronic Lyme disease and the role of antibiotic stewardship in treatment programs.
Segment Description: Samuel, Shor, MD, FACP, past president, International Lyme and Associated Diseases Society, explores the controversial concept of chronic Lyme disease and the role of antibiotic stewardship in treatment programs.
Interview Transcript (modified slightly for readability):
“The controversy in treating Lyme disease is particularly in relation to the concept of chronic Lyme disease, or that which involves active infection of the organism Borrelia burgdorferi that is responsible for perpetuation of ongoing symptoms for at least 6 months. There are 2 categories that I believe fit into this paradigm. One is those who never got diagnosed [and], in essence, are untreated—which is a large group—and the other is what’s characterized as post-treatment group.
